The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Cancer gender disparity in incidence, disease aggressiveness and prognosis has been
observed in a variety of cancers. Thyroid cancer is one of the fastest growing cancer …

Context BRAFV600E mutant thyroid cancers are often refractory to radioiodine (RAI).
Objectives To investigate the utility and molecular underpinnings of enhancing lesional …

BACKGROUND: The effects of the BRAFV600E mutation on prognostic factors and poor
clinical outcomes in papillary thyroid cancer (PTC) have not been fully quantified. The …

In recent years, the T1799A B-type Raf kinase (BRAF) mutation in thyroid cancer has
received enthusiastic investigation, and significant progress has been made toward …

Objective No consensus exists on the association between papillary thyroid carcinoma
(PTC) and Hashimoto's thyroiditis (HT). To resolve this controversy, this study aimed to …

Papillary thyroid cancer (PTC) is the most prevalent form of malignancy among all cancers of
the thyroid. It is also one of the few cancers with a rapidly increasing incidence. PTC is …

Clinicians have long sought to characterize biological markers of neoplasia as objective
indicators of tumor presence, pathogenicity, and prognosis. Armed with data that correlate …

Background There have been conflicting data regarding the prevalence and
clinicopathological characteristics of BRAF and NRAS mutations in primary cutaneous …

Background: The BRAFV600E mutation is the most frequent genetic alteration in papillary
thyroid carcinoma (PTC). The role of BRAFV600E mutation as a poor prognostic factor has …